MX2017001531A - Anticuerpos anti-trem2 y metodos de uso de los mismos. - Google Patents
Anticuerpos anti-trem2 y metodos de uso de los mismos.Info
- Publication number
- MX2017001531A MX2017001531A MX2017001531A MX2017001531A MX2017001531A MX 2017001531 A MX2017001531 A MX 2017001531A MX 2017001531 A MX2017001531 A MX 2017001531A MX 2017001531 A MX2017001531 A MX 2017001531A MX 2017001531 A MX2017001531 A MX 2017001531A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- trem2
- disease
- trem2 antibodies
- dementia
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
La invencion se dirige en general a metodos y composiciones que incluyen anticuerpos, por ejemplo, anticuerpos monoclonales, quimericos, humanizados, fragmentos de anticuerpos, etc., que enlazan especificamente una proteina TREM2, por ejemplo, una TREM2 de mamifero y/o TREM2 humana. Los metodos proporcionados en la presente encuentran uso en prevenir, reducir el riesgo, o tratar un individuo que tiene demencia, demencia frontotemporal, enfermedad de Alzheimer, enfermedad de Nasu-Hakola, o esclerosis multiple.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462035336P | 2014-08-08 | 2014-08-08 | |
US201562135110P | 2015-03-18 | 2015-03-18 | |
US201562135122P | 2015-03-18 | 2015-03-18 | |
PCT/US2015/044396 WO2016023019A2 (en) | 2014-08-08 | 2015-08-08 | Anti-trem2 antibodies and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017001531A true MX2017001531A (es) | 2017-05-15 |
Family
ID=55264791
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017001531A MX2017001531A (es) | 2014-08-08 | 2015-08-08 | Anticuerpos anti-trem2 y metodos de uso de los mismos. |
MX2023000334A MX2023000334A (es) | 2014-08-08 | 2017-02-02 | Anticuerpos anti-trem2 y metodos de uso de los mismos. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023000334A MX2023000334A (es) | 2014-08-08 | 2017-02-02 | Anticuerpos anti-trem2 y metodos de uso de los mismos. |
Country Status (12)
Country | Link |
---|---|
US (4) | US20170240631A1 (es) |
EP (2) | EP3177322A4 (es) |
JP (3) | JP6669749B2 (es) |
CN (1) | CN107106679B (es) |
AU (2) | AU2015300787A1 (es) |
CA (2) | CA2955086A1 (es) |
EA (1) | EA201790342A1 (es) |
HK (1) | HK1243006A1 (es) |
IL (2) | IL279606B (es) |
MX (2) | MX2017001531A (es) |
SG (2) | SG10201913611QA (es) |
WO (1) | WO2016023019A2 (es) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201913611QA (en) | 2014-08-08 | 2020-03-30 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
EP3197495A4 (en) | 2014-09-28 | 2018-08-29 | The Regents of The University of California | Modulation of stimulatory and non-stimulatory myeloid cells |
WO2017058866A1 (en) * | 2015-09-28 | 2017-04-06 | Precision Immune, Inc. | Anti-trem2 antibodies and uses thereof |
KR20180068999A (ko) * | 2015-10-06 | 2018-06-22 | 알렉터 엘엘씨 | 항-trem2 항체 및 그의 사용방법 |
MX2018008939A (es) | 2016-01-22 | 2019-08-21 | Merck Sharp & Dohme | Anticuerpos anti-factor de la coagulacion xi. |
KR102218714B1 (ko) | 2016-06-14 | 2021-02-24 | 머크 샤프 앤드 돔 코포레이션 | 항응고 인자 xi 항체 |
JP2019531332A (ja) * | 2016-07-22 | 2019-10-31 | ドイチェス ツェントルム フュール ノイロデゲネラティフェ アークランクンゲン エー.ファウ.(デーツェットエンエー) | Trem2切断モジュレーター及びその使用 |
JOP20190243A1 (ar) * | 2017-04-12 | 2019-10-13 | Medimmune Llc | علاج الربو بجسم مضاد لـ tslp |
CN108727489B (zh) * | 2017-04-19 | 2021-02-09 | 广州市第八人民医院 | 一种单克隆抗体zk2c2及应用 |
JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
EP3652749A4 (en) | 2017-07-14 | 2021-03-24 | The Regents of The University of California | NEW PROCESSES FOR PREDICTING THE RISK OF GRAFT REJECTION |
EP3601358B1 (en) * | 2017-08-03 | 2023-05-17 | Alector LLC | Anti-trem2 antibodies and methods of use thereof |
US20200277373A1 (en) * | 2017-09-14 | 2020-09-03 | Denali Therapeutics Inc. | Anti-trem2 antibodies and methods of use thereof |
US20200276335A1 (en) * | 2017-10-03 | 2020-09-03 | Prevail Therapeutics, Inc. | Gene therapies for lysosomal disorders |
EP3723803A4 (en) | 2017-12-12 | 2021-09-15 | Pionyr Immunotherapeutics, Inc. | ANTI-TREM2 ANTIBODIES AND RELATED METHODS |
AU2018393076A1 (en) | 2017-12-19 | 2020-07-02 | Surrozen Operating, Inc. | Anti-LRP5/6 antibodies and methods of use |
WO2019126398A1 (en) * | 2017-12-19 | 2019-06-27 | Surrozen, Inc. | Wnt surrogate molecules and uses thereof |
JP7418332B2 (ja) * | 2017-12-19 | 2024-01-19 | スロゼン オペレーティング, インコーポレイテッド | 抗フリズルド抗体及び使用方法 |
CN111886246A (zh) * | 2017-12-29 | 2020-11-03 | 艾莱克特有限责任公司 | 抗tmem106b抗体及其使用方法 |
BR112020023844A2 (pt) * | 2018-05-25 | 2021-04-13 | Alector Llc | Anticorpos, métodos de tratamento do câncer e de produção de um anticorpo, ácido nucleico, vetor, células hospedeiras e composição farmacêutica |
CA3106535A1 (en) * | 2018-07-27 | 2020-01-30 | Alector Llc | Anti-siglec-5 antibodies and methods of use thereof |
JP2022500081A (ja) * | 2018-09-11 | 2022-01-04 | ワシントン・ユニバーシティWashington University | 抗trem−2アゴニスト抗体 |
UY38407A (es) * | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
KR102156165B1 (ko) * | 2018-10-29 | 2020-09-15 | 재단법인대구경북과학기술원 | 인간 trem2 세포막 단백질에 대한 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도 |
EP3887401A2 (en) | 2018-11-26 | 2021-10-06 | Denali Therapeutics Inc. | Methods for treating dysregulated lipid metabolism |
WO2020121195A1 (en) * | 2018-12-10 | 2020-06-18 | Mor Research Applications | Trem2 antibodies and uses thereof |
AU2019397479A1 (en) * | 2018-12-11 | 2021-07-29 | Pionyr Immunotherapeutics, Inc. | Methods of using anti-TREM2 antibodies |
CN109646668B (zh) * | 2019-01-04 | 2019-10-18 | 厦门大学 | 一种多肽用于制备防治阿尔茨海默病药物的用途 |
TW202045543A (zh) * | 2019-02-20 | 2020-12-16 | 美商戴納立製藥公司 | 抗trem2抗體及其使用方法 |
WO2020194317A1 (en) * | 2019-03-28 | 2020-10-01 | Yeda Research And Development Co. Ltd. | Method of treating lipid-related disorders |
CN110320368A (zh) * | 2019-05-30 | 2019-10-11 | 广州医科大学附属第一医院(广州呼吸中心) | 基于trem2的诊断试剂盒及其在帕金森病诊断产品上的应用 |
AU2020310843A1 (en) * | 2019-07-05 | 2022-01-20 | University Of Florida Research Foundation, Incorporated | Methods for treating RAN protein-associated neurological diseases |
EP3999543A1 (en) * | 2019-07-15 | 2022-05-25 | Bristol-Myers Squibb Company | Anti-trem-1 antibodies and uses thereof |
WO2021055329A1 (en) * | 2019-09-16 | 2021-03-25 | Surface Oncology, Inc. | Anti-cd39 antibody compositions and methods |
JP7368624B2 (ja) | 2019-11-22 | 2023-10-24 | イーライ リリー アンド カンパニー | Trem2抗体およびそれらの使用 |
CN111000978B (zh) * | 2019-11-22 | 2023-03-10 | 中山大学附属第五医院 | Tlt-2在制备治疗结核病药物中的应用 |
AU2021208482A1 (en) | 2020-01-13 | 2022-07-21 | Denali Therapeutics Inc. | Anti-TREM2 antibodies and methods of use thereof |
IL272390A (en) | 2020-01-30 | 2021-08-31 | Yeda Res & Dev | Cancer treatment methods |
WO2021174003A2 (en) * | 2020-02-26 | 2021-09-02 | Washington University | Compositions and methods for reducing resistance to or enhancing immunotherapy |
CR20230069A (es) * | 2020-08-05 | 2023-08-16 | Vigil Neuroscience Inc | Tratamiento de enfermedades relacionadas con la disfunción del receptor del factor 1 estimulante de colonias con agonistas de trem2 |
CN112526143B (zh) * | 2020-12-03 | 2021-08-03 | 中山大学附属第五医院 | 髓系细胞触发受体2作为新型冠状病毒肺炎诊断或治疗靶点的应用 |
CN113150130B (zh) * | 2021-01-31 | 2022-10-18 | 中南大学湘雅医院 | 新型冠状病毒单克隆抗体及其应用 |
TW202330614A (zh) * | 2021-11-22 | 2023-08-01 | 美商維佳神經科學有限公司 | 抗trem2抗體及其用途 |
WO2023114499A1 (en) | 2021-12-17 | 2023-06-22 | Denali Therapeutics Inc. | Polypeptide engineering, libraries, and engineered cd98 heavy chain and transferrin receptor binding polypeptides |
JP7452918B2 (ja) | 2021-12-22 | 2024-03-19 | 国立大学法人 鹿児島大学 | マクロファージの製造方法、分化誘導剤、分化誘導キット、マクロファージの分化誘導方法、マクロファージの増殖促進剤、マクロファージの増殖促進キット、マクロファージの増殖方法及びマクロファージ |
WO2023150724A2 (en) * | 2022-02-04 | 2023-08-10 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind b7-h3 |
WO2023159140A2 (en) * | 2022-02-17 | 2023-08-24 | Adimab, Llc | Anti-asgr1 polypeptides and methods of use for immune tolerance |
CN114395034B (zh) * | 2022-03-24 | 2022-08-05 | 中国科学院微生物研究所 | 一种高效中和新型冠状病毒的人源抗体及其应用 |
WO2023192282A1 (en) | 2022-03-28 | 2023-10-05 | Denali Therapeutics Inc. | Methods for treating brain glucose hypometabolism |
WO2023192288A1 (en) | 2022-03-28 | 2023-10-05 | Denali Therapeutics Inc. | Monovalent anti-trem2 binding molecules and methods of use thereof |
WO2024052343A1 (en) | 2022-09-06 | 2024-03-14 | Institut National de la Santé et de la Recherche Médicale | Trem-2 agonists for the treatment of marfan syndrome |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
EP1997894B1 (en) | 1992-02-06 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Biosynthetic binding protein for cancer marker |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
AU668423B2 (en) | 1992-08-17 | 1996-05-02 | Genentech Inc. | Bispecific immunoadhesins |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
DE69637481T2 (de) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
JP2002514895A (ja) | 1995-09-28 | 2002-05-21 | アレクション、ファーマスーティカルズ、インコーポレーテッド | ブタ細胞相互作用タンパク質 |
DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
EP2305027B1 (en) | 1996-12-03 | 2014-07-02 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
ES2375931T3 (es) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
AU4834999A (en) | 1998-06-26 | 2000-01-17 | Incyte Pharmaceuticals, Inc. | Human signal peptide-containing proteins |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
MXPA02003456A (es) | 1999-10-04 | 2002-10-23 | Medicago Inc | Metodo para regular la transcripcion de genes foraneos. |
US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
CA2342376C (en) | 2001-03-20 | 2013-11-12 | Marco Colonna | A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
US8231878B2 (en) | 2001-03-20 | 2012-07-31 | Cosmo Research & Development S.P.A. | Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
US20090081199A1 (en) | 2001-03-20 | 2009-03-26 | Bioxell S.P.A. | Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
US8981061B2 (en) * | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
EP1508340A4 (en) | 2002-05-24 | 2009-07-01 | Takeda Pharmaceutical | MEANS FOR IMPROVING INSULIN RESISTANCE |
JP2004073182A (ja) | 2002-05-24 | 2004-03-11 | Takeda Chem Ind Ltd | インスリン抵抗性改善剤 |
JP2006504971A (ja) | 2002-11-01 | 2006-02-09 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド,ア・ボディー・コーポレイト | マトリックス支援レーザー脱離イオン化−飛行時間型質量分析によるタンパク質アイソフォームの定量的解析 |
CA2503390A1 (en) | 2002-11-01 | 2004-05-21 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
WO2004074506A2 (en) | 2003-02-13 | 2004-09-02 | Mergen Ltd | Polynucleotide sequences and corresponding encoded polypeptides of particular secreted and membrane-bound proteins overexpressed in certain cancers |
AP2007004034A0 (en) | 2004-12-31 | 2007-06-30 | Genentech Inc | Polypeptides sthat bind br3 and uses thereof |
US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
EP2001490A1 (en) | 2006-03-15 | 2008-12-17 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
WO2008042261A2 (en) | 2006-09-28 | 2008-04-10 | Elusys Therapeutics, Inc. | Anti-anthrax antibody, formulations thereof, and methods of use |
US7673853B2 (en) | 2006-10-12 | 2010-03-09 | Cordell Eldred Ebeling | Fencing section with adjustable fencing members |
UY30776A1 (es) | 2006-12-21 | 2008-07-03 | Medarex Inc | Anticuerpos cd44 |
US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
AU2008298603B2 (en) | 2007-09-14 | 2015-04-30 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
EP2186928A1 (en) | 2008-11-14 | 2010-05-19 | Enthone, Inc. | Method for the post-treatment of metal layers |
FR2945538B1 (fr) | 2009-05-12 | 2014-12-26 | Sanofi Aventis | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
TWI653333B (zh) | 2010-04-01 | 2019-03-11 | 安進研究(慕尼黑)有限責任公司 | 跨物種專一性之PSMAxCD3雙專一性單鏈抗體 |
DK2593594T3 (en) | 2010-07-16 | 2017-12-11 | Adimab Llc | ANTIBODY LIBRARIES |
US20130015055A1 (en) * | 2011-07-11 | 2013-01-17 | Hariharakeshava Sarpangala Hegde | Dual plasma source systems and methods for reactive plasma deposition |
WO2014074942A1 (en) * | 2012-11-08 | 2014-05-15 | Illumina, Inc. | Risk variants of alzheimer's disease |
SG10201913611QA (en) | 2014-08-08 | 2020-03-30 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
EP3197495A4 (en) | 2014-09-28 | 2018-08-29 | The Regents of The University of California | Modulation of stimulatory and non-stimulatory myeloid cells |
WO2016064895A1 (en) | 2014-10-20 | 2016-04-28 | The Brigham And Women's Hospital, Inc. | Targeting apolipoprotein e (apoe) in neurologic disease |
WO2017058866A1 (en) | 2015-09-28 | 2017-04-06 | Precision Immune, Inc. | Anti-trem2 antibodies and uses thereof |
KR20180068999A (ko) | 2015-10-06 | 2018-06-22 | 알렉터 엘엘씨 | 항-trem2 항체 및 그의 사용방법 |
JP2019531332A (ja) | 2016-07-22 | 2019-10-31 | ドイチェス ツェントルム フュール ノイロデゲネラティフェ アークランクンゲン エー.ファウ.(デーツェットエンエー) | Trem2切断モジュレーター及びその使用 |
JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
EP3601358B1 (en) | 2017-08-03 | 2023-05-17 | Alector LLC | Anti-trem2 antibodies and methods of use thereof |
US20200277373A1 (en) | 2017-09-14 | 2020-09-03 | Denali Therapeutics Inc. | Anti-trem2 antibodies and methods of use thereof |
EP3723803A4 (en) | 2017-12-12 | 2021-09-15 | Pionyr Immunotherapeutics, Inc. | ANTI-TREM2 ANTIBODIES AND RELATED METHODS |
-
2015
- 2015-08-08 SG SG10201913611QA patent/SG10201913611QA/en unknown
- 2015-08-08 IL IL279606A patent/IL279606B/en unknown
- 2015-08-08 CA CA2955086A patent/CA2955086A1/en active Pending
- 2015-08-08 CA CA3090240A patent/CA3090240A1/en active Pending
- 2015-08-08 MX MX2017001531A patent/MX2017001531A/es unknown
- 2015-08-08 SG SG11201700901SA patent/SG11201700901SA/en unknown
- 2015-08-08 CN CN201580054105.8A patent/CN107106679B/zh active Active
- 2015-08-08 AU AU2015300787A patent/AU2015300787A1/en not_active Abandoned
- 2015-08-08 WO PCT/US2015/044396 patent/WO2016023019A2/en active Application Filing
- 2015-08-08 EP EP15830235.6A patent/EP3177322A4/en not_active Ceased
- 2015-08-08 US US15/502,766 patent/US20170240631A1/en not_active Abandoned
- 2015-08-08 JP JP2017527545A patent/JP6669749B2/ja active Active
- 2015-08-08 EP EP21189092.6A patent/EP4066859A1/en active Pending
- 2015-08-08 EA EA201790342A patent/EA201790342A1/ru unknown
-
2017
- 2017-01-15 IL IL250115A patent/IL250115B/en unknown
- 2017-02-02 MX MX2023000334A patent/MX2023000334A/es unknown
-
2018
- 2018-02-26 HK HK18102736.5A patent/HK1243006A1/zh unknown
- 2018-09-21 US US16/138,761 patent/US20190010230A1/en not_active Abandoned
-
2019
- 2019-04-11 US US16/382,117 patent/US11084875B2/en active Active
- 2019-12-03 JP JP2019218512A patent/JP7326135B2/ja active Active
-
2021
- 2021-05-05 AU AU2021202840A patent/AU2021202840A1/en active Pending
-
2022
- 2022-02-28 JP JP2022029743A patent/JP2022081543A/ja not_active Withdrawn
- 2022-04-21 US US17/726,367 patent/US20230107639A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230107639A1 (en) | 2023-04-06 |
IL279606A (en) | 2021-03-01 |
US11084875B2 (en) | 2021-08-10 |
EP4066859A1 (en) | 2022-10-05 |
EP3177322A4 (en) | 2018-07-18 |
IL279606B (en) | 2022-08-01 |
EP3177322A2 (en) | 2017-06-14 |
US20190010230A1 (en) | 2019-01-10 |
CN107106679B (zh) | 2022-07-26 |
SG11201700901SA (en) | 2017-03-30 |
SG10201913611QA (en) | 2020-03-30 |
JP2020063268A (ja) | 2020-04-23 |
EA201790342A1 (ru) | 2017-07-31 |
CN107106679A (zh) | 2017-08-29 |
AU2021202840A1 (en) | 2021-06-03 |
WO2016023019A3 (en) | 2016-07-28 |
JP7326135B2 (ja) | 2023-08-15 |
IL250115B (en) | 2021-01-31 |
HK1243006A1 (zh) | 2018-07-06 |
JP2017523814A (ja) | 2017-08-24 |
JP2022081543A (ja) | 2022-05-31 |
JP6669749B2 (ja) | 2020-03-18 |
IL250115A0 (en) | 2017-03-30 |
WO2016023019A2 (en) | 2016-02-11 |
CA2955086A1 (en) | 2016-02-11 |
US20190315858A1 (en) | 2019-10-17 |
US20170240631A1 (en) | 2017-08-24 |
MX2023000334A (es) | 2023-02-09 |
AU2015300787A1 (en) | 2017-02-02 |
CA3090240A1 (en) | 2016-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023000334A (es) | Anticuerpos anti-trem2 y metodos de uso de los mismos. | |
WO2017062672A3 (en) | Anti-trem2 antibodies and methods of use thereof | |
PH12019502459A1 (en) | Anti-trem2 antibodies and methods of use thereof | |
MX2017012802A (es) | Anticuerpos antisortilina y métodos para su uso. | |
WO2017075432A3 (en) | Anti-siglec-9 antibodies and methods of use thereof | |
WO2016201388A3 (en) | Anti-cd33 antibodies and methods of use thereof | |
WO2016201389A3 (en) | Anti-cd33 antibodies and methods of use thereof | |
MX2018012757A (es) | Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos. | |
MX2022011002A (es) | Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos. | |
WO2017152102A3 (en) | Anti-trem1 antibodies and methods of use thereof | |
SA517381703B1 (ar) | C10orf54 - أجسام مضادة لـ واستخداماتها | |
GEP20207162B (en) | Lag-3-binding molecules and methods of use thereof | |
EP4249515A3 (en) | Humanized or chimeric cd3 antibodies | |
PH12019502463A1 (en) | Anti-cd33 antibodies and methods of use thereof | |
GEP20227438B (en) | Pd-1-binding molecules and methods of use thereof | |
PH12021550041A1 (en) | Anti-sortilin antibodies and methods of use thereof | |
PH12017502020A1 (en) | Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor | |
MX2021000933A (es) | Anticuerpos anti-siglec-5 y métodos para su uso. | |
NZ730186A (en) | Humanized anti-hepcidin antibodies and uses thereof | |
MX2019009498A (es) | Anticuerpos mimeticos de fgf21 y usos de los mismos. | |
TW201613977A (en) | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use | |
WO2012139069A3 (en) | Compositions and methods for treating diseases of protein aggregation involving ic3b deposition | |
WO2015117088A3 (en) | Antibody based reagents that specifically recognize neurodegenerative disease related forms of the protein tdp-43 | |
MA40536A (fr) | Anticorps anti-alpha v bêta 5 humanisés et leurs utilisations | |
WO2014144616A3 (en) | Anti-alpha v beta 5 antibodies and uses thereof |